Therapeutic approach to giant cell arteritis

Joint Bone Spine

Volumn 79, Issue 3, 2012, Pages 219-227

  Masson, Charles ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Giant cell arteritis; Glucocorticoid therapy; Horton's disease; Inflammatory syndrome; Interleukin 6; Polymyalgia rheumatic; Tocilizumab

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GAMMA INTERFERON; GLUCOCORTICOID; GOLD; HAPTOGLOBIN; HYDROCORTISONE; HYDROXYCHLOROQUINE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 32; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OROSOMUCOID; PREDNISOLONE; PREDNISONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ACUTE PHASE RESPONSE; ADRENAL CORTEX ATROPHY; ADRENAL CORTEX INSUFFICIENCY; AGRANULOCYTOSIS; ANEMIA; ANXIETY; ARTERY OCCLUSION; AVASCULAR NECROSIS; AXILLARY ARTERY; BLOOD VESSEL INJURY; BRACHIAL ARTERY; BULIMIA; CATARACT; CLINICAL FEATURE; CLINICAL PROTOCOL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIAPHORESIS; DIPLOPIA; DISEASE COURSE; DIVERTICULITIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EUPHORIA; EXTERNAL CAROTID ARTERY; FEMORAL ARTERY; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; GIANT CELL ARTERITIS; GLAUCOMA; HEART PALPITATION; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; LIFE EXPECTANCY; LOW DRUG DOSE; MENTAL DISEASE; METHEMOGLOBINEMIA; MOON FACE; MORTALITY; MYOPATHY; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PURPURA; REBOUND; RELAPSE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; SKIN ATROPHY; SUBCLAVIAN ARTERY; TH1 CELL; TH17 CELL; THORACIC AORTA; TRANSITIONAL BLINDNESS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTEBRAL ARTERY; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL, HUMANIZED; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6;

EID: 84860572416     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.09.015     Document Type: Short Survey

References (76)

1. Salvarani C., Cantini F., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008, 372:234-245.
2. Devauchelle-Pensec V., Jousse S., Destombe C., et al. Epidemiology, imaging, and treatment of giant cell arteritis. Joint Bone Spine 2008, 75:267-272.
3. Kawasaki A., Purvin V. Giant cell arteritis: an updated review. Acta Ophtalmologica 2009, 87:13-32.
4. Deng J., Younge B.R., Olshen R.A., et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010, 121:906-915.
5. Masson C. Rheumatoid anemia. Joint Bone Spine 2011, 78:131-137.
6. Soubrier M., Dubost J.J., Ristori J.M. Polymyalgia rheumatica: diagnosis and treatment. Joint Bone Spine 2006, 73:599-605.
7. Masson C. Pseudopolyarthrite rhizomélique, MH. Critères de diagnostic et de suivi. Rev Rhum Monographies 2010, 77:76-81.
8. Schmidt W.A., Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology 2002, 41:46-52.
9. Schmidt W.A., Seifert A., Grommica-Ihle E., et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology 2008, 47:96-101.
10. Schmidt W.A., Krause A., Schicke B., et al. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis?. Rheumatology 2009, 48:383-385.
11. Arida A., Kyprianou M., Kanakis M., et al. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord 2010, 11:44.
12. Geiger J., Ness T., Uhl M., et al. Involvement of the ophtalmic artery in giant cell arteritis visualized by 3T MRI. Rheumatology 2009, 48:537-541.
13. Bley T.A., Weiben O., Uhl M., et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 2005, 52:2470-2477.
14. Blockmans D., De Ceuninck L., Vanderschueren S., et al. Repetitive 18-Fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 2007, 46:672-677.
15. Blockkmans D., de Ceuninck L., Vanderschueren S., et al. 18F-Fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Care Res 2006, 55:131-137.
16. Chatelain D., Duhaut P., Schmidt J., et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 2009, 68:84-88.
17. Ciccia F., Alessandro R., Rizzo A., et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 2011, 63:2097-2104.
18. Younge B.R., Weyand C.M., Goronzy J.J. Occurrence of giant cell arteritis ... suddenly. Trans Am Ophtalmol Soc 2007, 105:141-145.
19. Dasgupta B., Borg F.A., Hassan N., et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010, 49:1594-1597.
20. Fraser J.A., Weyand C.M., Newman N.J., et al. The treatment of giant cell arteritis. Rev Neurol Dis 2008, 5:140-152.
21. Gonzalez-Gay M.A., Blanco R., Rodriguez-Valverde V., et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998, 41:1497-1504.
22. Liozon E., Herrmann F., Ly K., et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001, 111:211-217.
23. Liozon E., Boutros-Toni F., Ly K., et al. Silent or masked giant cell arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol 2003, 30:1272-1276.
24. Hernandez-Rodriguez J., Segarra M., Vilardell C., et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003, 107:2428-2434.
25. Lopez-Diaz M.J., Llorca J., Gonzalez-Juanatey C., et al. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Sem Arthritis Rheum 2008, 38:116-123.
26. Gonzalez-Gay M.A., Pineiro A., Gomez-Gigirey A., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic comlications in giant cell arteritis. Medicine (Baltimore) 2004, 83:342-347.
27. Tehrani R., Ostrowski R.A., Hariman R., et al. Giant cell arteritis: oral versus intravenous corticosteroids. Neuro-Ophtalmol 2009, 33:5-9.
28. Mazlumzadeh M., Hunder G.G., Easley K.A., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids. A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006, 54:3310-3318.
29. Binard A., De Bandt M., Berthelot J.M., et al. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 2008, 59:263-269.
30. Bley T.A., Markl M., Schelp M., et al. Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 2008, 47:65-67.
31. Roche N.E., Fulbright J.W., Wagner A.D., et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993, 36:1286-1294.
32. Younge B.R., Cook B.E., Bartley G.B., et al. Initiation of glucocorticoid therapy: before or after temporal artery biopsy?. Mayo Clin Proc 2004, 79:483-491.
33. Martinez-Lado L., Calvino-Diaz C., Pineiro A., et al. Relapses and recurrences in giant cell arteritis. A population-based study of patients with biopsy-proven disease from Northwestern Spain. Medicine 2011, 90:186-193.
34. Hernandez-Rodriguez J., Font C., Garcia-Martinez A., et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica. Study of a series of 100 patients. Medicine 2007, 86:233-241.
35. Assie C., Janvresse A., Plissonnier D., et al. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis. A series of 36 patients. Medicine 2011, 90:40-51.
36. Both M., Schulte K., Moosig F., et al. High white blood cell count in patients with giant cell arteritis predicts an increased risk of stenosis in upper extremity arteries. Ann Rheum Dis 2011, 10.1136/ard.2010.146910.
37. Yterberg S.R., Warrington K.J., Aletaha D., et al. Vasculitis working group: selected unanswered questions related to giant cell arteritis and anti-neutrophil cytoplasmic antibody-associated vasculitis. Joint Bone Spine 2009, 76:440-443.
38. Le Hello C., Levesque H., Jeanton M., et al. Lower limb giant cell arteritis and temporal arteritis: followup of 8 cases. J Rheumatol 2001, 28:1407-1412.
39. Rüegg S., Engelter S., Jeanneret C., et al. Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature. Medicine (Baltimore) 2003, 82:1-12.
40. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gomez-Acebo I., et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine 2009, 88:227-235.
41. Nuenninghoff D.M., Hunder G.G., Christianson T.J.H., et al. Mortality of large-artery complication (aortic aneuvrysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. A population-based study over 50 years. Arthritis Rheum 2003, 48:3532-3537.
42. Gonzalez-Gay M.A., Garcia-Porrua C., Pineiro A., et al. Aortic aneuvrysm and dissection in patients with biopsy-proven giant cell arteritis from Northwestern Spain. A population-based study. Medicine 2004, 83:335-341.
43. Tavora F., Burke A. Review of isolated ascending aortitis: differential diagnosis, including syphilitic, Takayasu's and giant cell aortitis. Pathology 2006, 38:302-308.
44. Burke A.P., Tavora F., Narula N., et al. Aortitis and ascending aortic aneuvrysm: description of 52 cases and proposal of a histological classification. Hum Pathol 2008, 39:514-526.
45. Agard C., Barrier J.H., Dupas B., et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case control prospective study using helical aortic computed tomodensitometric scan. Arthritis Care Res 2008, 59:670-676.
46. Bossert M., Prati C., Balblanc J.C., et al. Aortic involvement in giant cell arteritis: current data. Joint Bone Spine 2011, 78:246-251.
47. Salvarini C., Calamia K.T., Matteson E.L., et al. Vasculitis of the gastrointestinal tract in chronic periaortitis. Medicine 2011, 90:28-39.
48. Palazzi C, Salvarini C, D'Angelo S, et al. Aortitis and periaortitis in ankylosing spondylitis. Joint Bone Spine 2011;78:451-5, doi: 10.1016/j.bspin2010.11.003.
49. Hernandez-Rodriguez J., Garcia-Martinez A., Casademont J., et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Care Res 2002, 47:29-35.
50. Myklebust G., Gran J.T. Prednisone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol 2001, 30:260-267.
51. Goichot B., Vinzio S., Luca F., et al. Que reste-t-il de l'insuffisance surrénale post-MH ?. Presse Med 2007, 36:1065-1071.
52. Mahr A., Saba M., Kambouchner M., et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?. Ann Rheum Dis 2006, 65:826-828.
53. Genereau T., Lortholary O., Pottier M.A., et al. Temporal artery biopsy. A diagnostic tool for systemic necrotizing vasculitis. Arthritis Rheum 1999, 42:2674-2681.
54. Prokesch B., Law K., Conn D.L. Thromboangiitis involving the temporal artery. Arthritis Care Res 2011, 63:918-920.
55. Nesher G., Berkun Y., Mates M., et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332-1337.
56. Lee M.S., Smith S.D., Galor A., et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006, 54:3306-3309.
57. Salvarini C., Cimino L., Macchioni P., et al. Risk factors for visual loss in italian population-based cohort of patients with giant cell arteritis. Arthritis Care Res 2005, 53:293-297.
58. Bloch J., Morell-Dubois S., Koch E., et al. Hallucinations visuelles et maladies de Horton : à propos du syndrome de Charles Bonnet. Rev Med Interne 2011, 10.1016/j.revmed.2010.12.014.
59. Kermani T.A., Schäfer V.S., Crowson C.S., et al. Cancer preceding giant cell arteritis. A case-control study. Arthritis Rheum 2010, 62:1763-1769.
60. Kermani T.A., Schäfer V.S., Crowson C.S., et al. Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res 2010, 62:149-154.
61. Proven A., Gabriel S.E., Orces C., et al. Glucocorticoid thrapy in giant cell arteritis: duration and adverse outcomes. Arthritis Care Res 2003, 49:703-708.
62. Weyand C.M., Fulbright J.W., Hunder G.G., et al. Treatment of giant cell arteritis. Interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000, 43:1041-1048.
63. Mahr A.D., Jover J.A., Spiera R.F., et al. Adjunctive methotrexate for treatment of giant cell arteritis. An individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789-2797.
64. Pham T., Bachelez H., Berthelot J.M., et al. TNFalpha antagonist therapy and safety monitoring. Joint Bone Spine 2011, 78:S15-S185.
65. Martinez-Taboada V.M., Rodriguez-Valverde V., Cerreno L., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
66. Kreiner F., Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther 2010, 12:R176.
67. Leydet-Quilici H., Luc M., Armingeat T., et al. Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. Joint Bone Spine 2007, 74:303-304.
68. Watson P., Gaston H. Response to effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther 2011, 13:403.
69. Beyer C., Axmann R., Sahinbegovic E., et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011, 10.1136/ard.2010.149351.
70. Seitz M., Reichenbach S., Bonel H.M., et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss Med Wkly 2011, 141:w13156.
71. Pham T., Claudepierre P., Constantin A., et al. Tocilizumab therapy and safety management. Joint Bone Spine 2010, 77:S3-S100.
72. Gran J.T., Myklebust G., Wilsgaard T., et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology 2001, 40:1238-1242.
73. Gonzalez-Gay M.A., Rubiera G., Pineiro A., et al. Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. J Rheumatol 2005, 32:502-506.
74. Crow RW, Katz BJ, Warner JEA, et al. Giant cell arteritis and mortality. J Gerontol 2007.
75. Wade Crow R., Katz B.J., Warner J.E.A., et al. Giant cell arteritis and mortality. J Gerontol 2009, 64A:365-369.
76. Uddhammar A., Eriksson A.L., Nystrom L., et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002, 29:737-742.